multiple sclerosis

For December 2015 we have selected: Ramanujam R, Hedstrom A-K, Manouchehrinia A, et al. Effect of smoking cessation on multiple sclerosis prognosis. JAMA Neurol 2015; 72(10):1117-1123. The usual course of multiple sclerosis (MS) is characterized by the conversion to secondary progressive disease within about 20 years from the first attack. Great efforts are currently made to modify the disease progression with the use of aggressive and expensive medical treatments.

by Anna Sauerbier Open call: European Foundations Award for Responsible Research and Innovation (OSHA)
A consortium of European Foundations took the initiative to launch a new award: the European Foundations Award for Responsible Research and Innovation. European Commission signs agreement… Continue Reading

For August 2015, we have selected: Ngandu T, Lehtisalo J, Solomon A, et al. A 2-year multidomain intervention of diet, exercise, cognitive training, and vascular risk monitoring versus control to prevent cognitive decline in at-risk elderly people (FINGER): a randomized controlled trial. The Lancet Neurology 2015;385:2255-2263. The progressive aging of the world population and the related increased number of people with neurodegenerative disorders such as Alzheimer disease (AD) and other dementias, urge to find new and effective prevention strategies.

In this issue of the Neuropenews we would like to again invite you to read interesting articles which were kindly chosen by our Subspecialty Scientific Panel on Higher Cortical Functions: May-Britt Moser, David C. Rowland, Edvard I. Moser: “Place cells,… Continue Reading

The European Academy of Neurology (EAN) held its 1st Congress in Berlin, Germany, from 20 to 23 June. The EAN was set up last year following a merger between the European Federation of Neurological Societies (EFNS) and the European Neurological Society (ENS).

une 2015 is coming closer and the stage for the first congress will open on Saturday, the 20th. We expect more than 6000 participants from all over Europe and the world to come to the CityCube in Berlin, the brand new Berlin congress center, the venue of the congress.

Over the last months, Neuropenews has featured 8 chapters describing the beginning of neurology in Germany (chapter 1), a golden age at the end of the 19th century, the first 30 years of the 20th century with true scientific breakthroughs (chapter 2), the dark age before and during World War II (chapter 3), the slow and painful (chapter 4) and since the 1970ies accelerating recovery (chapter 5-8) of clinical neuroscience and neurology in Germany [1].

As in the previous year, Neuropenews asked EAN committee members, panel chairs, speakers etc. which session one should not miss at the upcoming congress in Berlin, June 2015. Please find their answers below! Benedikt Schoser, speaker at Symposium 3 “Modern… Continue Reading

As in the previous year, Neuropenews asked EAN committee members, panel chairs, speakers, … which session one should not miss at the upcoming congress in Berlin, June 2015. Please find their answers below …

To celebrate the European Journal of Neurology’s  first full volume as the official journal of the European Academy of Neurology it is publishing a series of invited review articles from European subspecialty experts covering topics of current interest. The first… Continue Reading

Neuropenews (NN) has as one of its constant features a Section, named “TOP 10”, with the list of the 10 most cited papers in the neurological literature over the preceding two (full) years, i.e. for the NN 2014 Issues, the publication years 2012 and 2013.

The first paper that I would like to point out to Neuropenews readers has been published in a very “peripheral” Journal, such as Missouri Medicine, at least in respect to European Neurology. However, the paper “Beta blocker eye drops for treatment of acute migraine”, by Migliazzo CV, and JC Hagan, Missouri Medicine, 111, 2014, 283-288 has been highly “tagged” by neurologists. Seven cases of acute migraine patients, successfully treated with beta blocker eye drops are reported.

The EAN is a young Society and our purpose is to promote ‘Excellence in Neurology in Europe’.  This task has many facets and one of them is to engage more people in the Society. This process is presently underway.

Report from Dr. Naida Nasrullayeva from Azerbaijan visiting the Department of Neurology at the University Hospital Copenhagen, Denmark under the supervision of Doctor Michael Oettinger. First of all, I would like to thank EFNS (EAN) for the opportunity to visit… Continue Reading

Franz Fazekas (FF): Building the EAN is a unique opportunity to strengthen the role and visibility of our specialty in patient care and clinical science throughout the continent and beyond.